Sinovac Biotech, Ltd (SVA) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts SVA Hot Sheet
Join SI Premium – FREE
Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q3 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $12.35 million.
For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.
For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AIR Global sets first-ever dividend, $100M buyback amid business, cash strength
- MdxHealth suspends 2026 guidance as Q3 revenue misses targets
- Prologis (PLD) Tops Q3 EPS by 8c; revises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
